Determinants of left ventricular hypertrophy and its progression in high-flux haemodialysis

Blood Purif. 2003;21(2):163-9. doi: 10.1159/000069155.

Abstract

Aim: To identify factors contributing to the development and progression of left ventricular hypertrophy (LVH) in patients on high-flux haemodialysis.

Method: Fifty patients without clinical cardiac disease underwent baseline echocardiography, related measurements and follow-up studies 6-12 months later.

Results: Residual urea clearance was lower (0.7 +/- 1.1 vs. 2.2 +/- 2.4 ml/min; p = 0.034) while systolic blood pressure (162 +/- 21 vs. 147 +/- 11 mm Hg; p = 0.003), duration of dialysis dependence (38 +/- 37 vs. 17 +/- 13 months; p = 0.004) and interdialytic weight gain (1.98 + 0.84 vs. 1.32 + 1.08 kg; p = 0.026) were higher in those with LVH. Parathyroid hormone changed less in those whose LVH regressed (186 +/- 89 vs. 303 +/- 280 pg/ml; p = 0.032). Regression did not occur when parathyroid hormone was >300 pg/ml. ACE gene polymorphism did not affect LVH development or progression.

Conclusion: Systolic hypertension, duration of dialysis dependence and high interdialytic weight gains promote LVH. Hyperparathyroidism retards LVH regression.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperparathyroidism / blood
  • Hyperparathyroidism / complications
  • Hypertension / epidemiology
  • Hypertrophy, Left Ventricular / diagnostic imaging
  • Hypertrophy, Left Ventricular / etiology*
  • Hypertrophy, Left Ventricular / physiopathology
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy*
  • Male
  • Middle Aged
  • Parathyroid Hormone / blood
  • Peptidyl-Dipeptidase A / genetics
  • Polymorphism, Genetic
  • Renal Dialysis / adverse effects*
  • Renal Dialysis / methods
  • Risk Factors
  • Ultrasonography
  • Weight Gain

Substances

  • Parathyroid Hormone
  • Peptidyl-Dipeptidase A